Search for content, post, videos

AstraZeneca divests rights to Arimidex and Casodex in Europe and certain additional countries

David Fredrickson

AstraZeneca has agreed to sell the commercial rights to Arimidex (anastrozole) and Casodex (bicalutamide) in a number of European, African and other countries1 to Juvisé Pharmaceuticals.

The medicines, used primarily to treat breast and prostate cancers, have lost their compound patent protection in these countries. AstraZeneca already divested the rights to both Arimidexand Casodex in the US in 2017.

“Arimidex and Casodex are important established medicines and we are pleased that Juvisé Pharmaceuticals will now take on the work of making sure patients continue to have access to them. Today’s agreement is part of a broader strategy of reducing our portfolio of mature medicines to reallocate resources towards developing our pipeline of new medicines,” says Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca.

Financial considerations

As there were no closing conditions to the divestment, the agreement became effective upon signing. Juvisé Pharmaceuticals has made an upfront payment of $181m to AstraZeneca and may also make future sales-contingent payments of up to $17m. Income arising from the upfront payment will be reported in AstraZeneca’s financial statements in the fourth quarter of 2019.

In 2018, Arimidex had sales of $37m in the countries covered by this agreement, while Casodex had sales of $24m.

Photo of Dave Fredrickson: AstraZeneca